Fast-track healthcare goals and enable personalization for every patient with pharmacogenomic-guided prescribing.
Pharmacogenomic (PGx) is the study of how genetic variations influence the way an individual responds to medications.
PGx is now enabling doctors to test for specific genetic changes to predict whether a patient may have a normal response, a poor response, or a higher risk of side effects before prescribing a specific medication.
We offer two PGX tests:
Covering 14 genes and over 41 psychotropic medications used in clinical practice. Find out more about the Psychotropic test.
Covering up to 24 genes and over 160 medications used in clinical practice. Find out more about the Multiple Category Test.
May help reduce the risk of experiencing medication side effects.
By testing certain genetic markers, the risk of possible side effects may be predicted even prior to starting the medication. This can help personalize dosage and choice of medication.
May reduce some of the guesswork around medication selection.
PGx testing may help to reduce some of the "trial and error" that can be involved in prescribing medications. The myDNA test provides you with information that can further assist in prescribing an effective medication sooner, potentially saving you and your patient time and money.
Results last a lifetime.
The test results presented in the report will assist you and your patient, now and in the future, to decide if one of the covered medications is right for your patient.
Patients with a current or past history of experiencing medication side effects.
Patients experiencing suboptimal response to medications.
Our clinical team includes clinical pharmacologists, clinical pharmacists, clinical geneticists, and genetic counselors.
CIA and CAP-accredited laboratory
10+ years of experience processing genetic samples
Less than 50% of patients are likely to have an adequate response to their first-line antidepressant.(1)
A recent meta-analysis has shown that patients who received pharmacogenomic-guided antidepressant treatment were more likely to achieve symptom remission compared to patients without pharmacogenomic-guided treatment. (2)
Peer-reviewed pharmacogenomic guidelines by international experts offer clinically actionable recommendations on specific gene-drug interactions covering many commonly prescribed psychotropic medications.(3-5)